Back to Authors

Gerdtsson, Axel

0000-0003-4033-5078

Mayo Clinic

Department of Clinical Science, Intervention and Technology, Division of Urology, Karolinska Institutet, Stockholm, Sweden.

Citations 1

Risk Factors for Relapse in Nonseminomatous Testicular Cancer After Postchemotherapy Retroperitoneal Lymph Node Dissection With Viable Residual Cancer

Journal of Clinical Oncology | September 1, 2023 | Volume: 41 | Issue: 34 | Pages: 5296-5305

10.1200/jco.23.00443 | PMID 37656935

What is the role of pcRPLND in men with retroperitoneal vital cancer after first-line chemotherapy? This question arises because of the potential predictive value of miR371 in identifying residual cancer even before pcRPLND! @cdfankhauser shared data within a multicenter cohort study redefining future practice in the miR371 era.